![](https://investorshub.advfn.com/uicon/750370.png?cb=1607199114)
Friday, June 24, 2022 12:13:46 PM
FDA accepts Company’s Data Access Plan to determine potential new clinical endpoints to support Emergency Use Authorization
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for #Bucillamine in #COVID19
— Revive Therapeutics (CSE: RVV, US: RVVTF) Official (@Revive_RVV) June 24, 2022
FDA accepts Company’s Data Access Plan to determine potential new clinical endpoints to support Emergency Use Authorization
Learn more: https://t.co/m0BhYm3fp3$RVV $RVVTF pic.twitter.com/ZpAivL5Tzk
https://revivethera.com/2022/06/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19-10/
FEATURED Mawson Finland Provides Update on Exploration Activities at Rajapalot • Aug 21, 2024 9:06 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM